The present disclosure relates to methods for maintaining a reduced body weight and/or body fat after initial weight reducing treatment or for attenuating or preventing or treating rebound of weight and/or fat gain following discontinuation of treatment with a GLP-1 receptor agonist. The methods comprises the administration of lignagliptin following weight loss treatment. The conditions may be type 2 diabetes, obesity or both. The GLP-1 receptor agonist can selected from exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide and dulaglutide. The weight loss treatment is administered to a overweight or obese patient with or without diabetes, particularly in a type 2 diabetes patient being obese or overweight.
